CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 57,610 enrolled
Drug / intervention
biphasic insulin aspartdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00659282
NCT00659282N/ACompleted
CompareCT.gov

Observational Study of Safety and Effectiveness of NovoMix® 30 (Biphasic Insulin Aspart) for the Treatment of Diabetes Mellitus

Novo Nordisk A/S·observational·Posted Apr 16, 2008·Updated Jan 12, 2018

In Brief

An observational study evaluating biphasic insulin aspart for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 57,610 participants across 11 sites in 11 countries.

Detailed Summary

This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the countries participating in the study. The primary outcome is the incidence of major hypoglycaemic events reported as serious adverse drugs reaction conditions on hypoglycaemic events.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, China, Greece, India, Iran, Italy, Japan, Poland, Russia, Saudi Arabia, South Korea
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2008
Enrollment StartSep 11, 2006
Primary CompletionNov 15, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.2 years ago

Interventions

biphasic insulin aspartdrug

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.